Literature DB >> 16142378

Relative imbalances in the expression of estrogen-metabolizing enzymes in the breast tissue of women with breast carcinoma.

Seema Singh1, Dhrubajyoti Chakravarti, James A Edney, Ronald R Hollins, Perry J Johnson, William W West, Sheila M Higginbotham, Ercole L Cavalieri, Eleanor G Rogan.   

Abstract

Estrogens are a known risk factor for breast cancer. Studies indicate that initiation of breast cancer may occur by metabolism of estrogens to form abnormally high levels of catechol estrogen-3,4-quinones, which can then react with DNA to form depurinating adducts and, subsequently, induce mutations that lead to cancer. Among the key enzymes metabolizing estrogens are two activating enzymes: cytochrome P450 (CYP)19 (aromatase), which converts androgens to estrogens, and CYP1B1, which converts estrogens predominantly to the 4-catechol estrogens that are further oxidized to catechol estrogen-3,4-quinones. Formation of the quinones is prevented by methylation of the 4-catechol estrogens by the enzyme, catechol-O-methyltransferase (COMT). In addition, catechol estrogen quinones can be reduced back to catechol estrogens by NADPH quinone oxidoreductase 1 (NQO1) and/or are coupled with glutathione, preventing reaction with DNA. Thus, COMT and NQO1 are key deactivating enzymes. In this initial study, we examined whether the expression of these four critical estrogen activating/deactivating enzymes is altered in breast cancer. Control breast tissue was obtained from four women who underwent reduction mammoplasty. Breast tissues from five women with breast carcinoma, who underwent mastectomy, were used as cases. The level of expression of CYP19, CYP1B1, COMT and NQO1 mRNAs was quantified from total RNA using a real time RT-PCR method in an ABI PRISM 7700 sequence detection system. The control breast tissues showed lower expression of the activating enzymes, CYP19 and CYP1B1, and higher expression of the deactivating enzymes, COMT and NQO1, compared to the cases. In the cases, the reverse pattern was observed: greater expression of activating enzymes and lower expression of deactivating enzymes. Thus, in women with breast cancer, estrogen metabolism may be related to altered expression of multiple genes. These unbalances appear to be instrumental in causing excessive formation of catechol estrogen quinones that, by reacting with DNA, initiate the series of events leading to breast cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16142378

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  24 in total

Review 1.  The molecular etiology and prevention of estrogen-initiated cancers: Ockham's Razor: Pluralitas non est ponenda sine necessitate. Plurality should not be posited without necessity.

Authors:  Ercole Cavalieri; Eleanor Rogan
Journal:  Mol Aspects Med       Date:  2013-08-30

2.  N-acetylcysteine blocks formation of cancer-initiating estrogen-DNA adducts in cells.

Authors:  Muhammad Zahid; Muhammad Saeed; Mohammed F Ali; Eleanor G Rogan; Ercole L Cavalieri
Journal:  Free Radic Biol Med       Date:  2010-05-31       Impact factor: 7.376

3.  Unbalanced estrogen metabolism in ovarian cancer.

Authors:  Muhammad Zahid; Cheryl L Beseler; James B Hall; Tricia LeVan; Ercole L Cavalieri; Eleanor G Rogan
Journal:  Int J Cancer       Date:  2014-01-25       Impact factor: 7.396

Review 4.  Depurinating estrogen-DNA adducts in the etiology and prevention of breast and other human cancers.

Authors:  Ercole L Cavalieri; Eleanor G Rogan
Journal:  Future Oncol       Date:  2010-01       Impact factor: 3.404

5.  Evaluation of serum estrogen-DNA adducts as potential biomarkers for breast cancer risk.

Authors:  Sandhya Pruthi; Li Yang; Nicole P Sandhu; James N Ingle; Cheryl L Beseler; Vera J Suman; Ercole L Cavalieri; Eleanor G Rogan
Journal:  J Steroid Biochem Mol Biol       Date:  2012-02-24       Impact factor: 4.292

Review 6.  NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector.

Authors:  Albena T Dinkova-Kostova; Paul Talalay
Journal:  Arch Biochem Biophys       Date:  2010-03-31       Impact factor: 4.013

7.  Loss of NQO1 generates genotoxic estrogen-DNA adducts in Fuchs Endothelial Corneal Dystrophy.

Authors:  Taiga Miyajima; Geetha Melangath; Shan Zhu; Neha Deshpande; Shivakumar Vasanth; Bodhisattwa Mondal; Varun Kumar; Yuming Chen; Marianne O Price; Francis W Price; Eleanor G Rogan; Muhammad Zahid; Ula V Jurkunas
Journal:  Free Radic Biol Med       Date:  2019-12-17       Impact factor: 7.376

8.  NAD(P)H:quinone oxidoreductase 1 Arg139Trp and Pro187Ser polymorphisms imbalance estrogen metabolism towards DNA adduct formation in human mammary epithelial cells.

Authors:  Seema Singh; Muhammad Zahid; Muhammad Saeed; Nilesh W Gaikwad; Jane L Meza; Ercole L Cavalieri; Eleanor G Rogan; Dhrubajyoti Chakravarti
Journal:  J Steroid Biochem Mol Biol       Date:  2009-07-21       Impact factor: 4.292

9.  Evidence from ESI-MS for NQO1-catalyzed reduction of estrogen ortho-quinones.

Authors:  Nilesh W Gaikwad; Eleanor G Rogan; Ercole L Cavalieri
Journal:  Free Radic Biol Med       Date:  2007-08-03       Impact factor: 7.376

10.  Sex steroid metabolism polymorphisms and mammographic density in pre- and early perimenopausal women.

Authors:  Carolyn J Crandall; Mary E Sehl; Sybil L Crawford; Ellen B Gold; Laurel A Habel; Lesley M Butler; Maryfran R Sowers; Gail A Greendale; Janet S Sinsheimer
Journal:  Breast Cancer Res       Date:  2009-07-27       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.